drugset / Trial / NCT05429905
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
Phase 1/2
Unknown
48 enrolled
KK Women's and Children's Hospital
National University Hospital, Singapore · collabSingapore General Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to deliver dual-targeting CAR-T cell therapy (CART 2219.1) as a salvage treatment to patients with relapsed/refractory B-lineage leukaemia in place of stem cell transplant or irradiation.
Timeline
- Start
- 2022-07-18
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART2219.1 | Cell therapy | 400000 cells/kg | Intravenous |
| Subject | CART2219.1 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CART2219.1 | Cell therapy | 2.5e+06 cells/kg | Intravenous |